PFS and OS in patients treated with daratumumab plus Kd. Median PFS in the all treated population and across subgroups (A), median PFS by cytogenetic risk group at baseline (B), and median OS in the all treated population and across subgroups (C) at a median follow-up of 16.6 months. Bort, bortezomib; Len, lenalidomide; NE, not evaluable.